Vermillion study demonstrates Overa’s sensitivity in ovarian cancer detection

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vermillion Inc. announced publication of a paper titled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (Shulman et al. Adv Ther. July 2019).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login